Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Subscribe To Our Newsletter & Stay Updated